La Jolla, CA – According to filings with the U.S. Securities and Exchange Commission, Resilience is raising $755,000,062.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, Sandy Mahatme played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Resilience

We offer reliability and innovation in manufacturing so our partners can focus on the discoveries that improve patients’ lives. The Resilience platform includes standardized processes, best-in-class quality and regulatory capabilities, innovative technologies, and smart informatics. Resilience offers a broad mix of customized manufacturing and development capabilities to serve the needs of biopharmaceutical companies at all stages of the drug development process  from pre-clinical development to commercial supply.

To learn more about Resilience, visit http://resilience.com/

Contact:
Sandy Mahatme, President and Chief Operating Officer
888-737-2460
https://www.linkedin.com/in/sandy-mahatme-77760130/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved